CHMP Adopts Positive Opinion Of Sandoz’s Herwenda® (Trastuzumab) Biosimilar To Genentech’s Herceptin®

Sep 15, 2023

The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Sandoz’s Herwenda® (trastuzumab, biosimilar to Genentech’s Herceptin®), to treat metastatic and early breast cancer and metastatic gastric cancer.

On the same day, Novartis’s shareholders approved the Sandoz spin-off which is scheduled for 4 October 2023.

Print Page Mail Article